BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Isuzinaxib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Isuzinaxib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06962098-372@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Isuzinaxib: Phase 2 readout est. (NCT06962098)
DESCRIPTION:Isuzinaxib\, phase 2\, Chronic Kidney Disease.\nStudy: Efficacy
  and Safety Study of Isuzinaxib in Subjects With DKD\nEstimated primary co
 mpletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/isuzinaxib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06962098
URL:https://assetmemo.bio/drug/isuzinaxib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
